ReviewJournal of neuro-oncology2010
Aberrant signaling pathways in meningiomas.
Review in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 71 citations in OpenAlex.
- A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.Journal of neuro-oncology · 2014Trial
- Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.Journal of neuro-oncology · 2012Trial
- A novel compound, SYHA1813, inhibits malignant meningioma growth directly by boosting p53 pathway activation and impairing DNA repair.Frontiers in oncology · 2025Article
- Homeodomain Transcription Factors Nkx2.2 and Pax6 as Novel Biomarkers for Meningioma Tumor Treatment.Indian journal of clinical biochemistry : IJCB · 2024Article
- Lifestyle and metabolic factors affect risk for meningioma in women: a prospective population-based study (The Cohort of Norway).Frontiers in oncology · 2024Article
- Signaling pathways in brain tumors and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- [Targeted Drug Therapy for Intracranial Tumors].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022Review
- Identification and Management of Aggressive Meningiomas.Frontiers in oncology · 2022Review
- Identification of Meningioma Patients at High Risk of Tumor Recurrence Using MicroRNA Profiling.Neurosurgery · 2020Article
- Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma.Journal of neuro-oncology · 2020Article
- Molecular characteristics of meningiomas.Journal of pathology and translational medicine · 2020Review
- An Overview of Managements in Meningiomas.Frontiers in oncology · 2020Review
- Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature.World journal of surgical oncology · 2019Review
- Genomic analysis of synchronous intracranial meningiomas with different histological grades.Journal of neuro-oncology · 2018Article
- Article
- Alterations of oxidative phosphorylation in meningiomas and peripheral nerve sheath tumors.Neuro-oncology · 2016Article
- Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.Neuro-oncology · 2015Article
- miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo.Oncogene · 2015Article
- Molecular Targets and Treatment of Meningioma.Journal of neurology and neurosurgery · 2014Article
- Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.BMC complementary and alternative medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this article, we provide a brief description of the current understanding of aberrant signaling pathways in meningiomas. Cell signaling pathways are responsible for cellular differentiation, development, growth, growth inhibition, and death. In fact, signaling pathways can affect multiple intracellular functions, including those responsible for development, angiogenesis, and apoptosis. Ultimately, a further understanding of the signaling pathways involved in meningioma tumorigenesis will lead to the development and application of novel molecular treatments, such as small molecule inhibitors or interfering ribonucleic acid technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.